Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P79.01 - TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezolizumab with Chemoradiation (AFT-16)

      00:00 - 00:00  |  Presenting Author(s): Woo Yul Byun

      • Abstract

      Loading...

    • +

      P79.02 - Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC

      00:00 - 00:00  |  Presenting Author(s): Caicun Zhou

      • Abstract

      Loading...

    • +

      P79.03 - A Phase 3 Study of the PD-1 Inhibitor Retifanlimab (INCMGA00012) Plus Platinum-Based Chemotherapy in 1L mNSCLC: POD1UM-304

      00:00 - 00:00  |  Presenting Author(s): Shun Lu

      • Abstract

      Loading...

    • +

      P79.04 - A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis.

      00:00 - 00:00  |  Presenting Author(s): Dwight H Owen

      • Abstract

      Loading...

    • +

      P79.05 - Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenting Author(s): Caroline Huynh

      • Abstract

      Loading...

    • +

      P79.06 - CHIO3: ChEmotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer (AFT-46)

      00:00 - 00:00  |  Presenting Author(s): Linda W Martin

      • Abstract

      Loading...

    • +

      P79.07 - Comparative Efficacy and Safety of PD-(L)1 Inhibitors Combined with 1st-Line Chemotherapy for Advanced NSCLC: A Meta-Analysis

      00:00 - 00:00  |  Presenting Author(s): Alessandro Di Federico

      • Abstract

      Loading...

    • +

      P79.08 - Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment

      00:00 - 00:00  |  Presenting Author(s): Shun Lu

      • Abstract

      Loading...

    • +

      P79.09 - Neoadjuvant Combination Sintilimab plus Chemotherapy in Patients with Resectable Stage IIIA Non-Small Cell Lung Cancer.

      00:00 - 00:00  |  Presenting Author(s): Kewei Ma

      • Abstract

      Loading...

  • +

    P80 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy/ Immunotherapy Plus Targeted Therapy

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P80.01 - A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC

      00:00 - 00:00  |  Presenting Author(s): Baohui Han

      • Abstract

      Loading...

  • +

    P81 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy/Immune Checkpoint Inhibitor Single Agent

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P81.01 - Efficacy and Safety of Camrelizumab in Patients with Advanced Lung Cancer: A Multicentre, Prospective, Observational Study.

      00:00 - 00:00  |  Presenting Author(s): Yong Qian Shu

      • Abstract

      Loading...

    • +

      P81.02 - Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors

      00:00 - 00:00  |  Presenting Author(s): Shikang Zhao

      • Abstract

      Loading...

  • +

    P82 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Radiotherapy

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P82.01 - Tumor Treating Fields (150 kHz) Concurrent with Immune Check Point Inhibitors for Stage 4 Non-Small Cell Lung Cancer (NSCLC) in Phase 3 LUNAR Study

      00:00 - 00:00  |  Presenting Author(s): Ticiana Leal

      • Abstract

      Loading...

    • +

      P82.02 - Stereotactic Ablative Radiotherapy with Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a phase 2 study

      00:00 - 00:00  |  Presenting Author(s): Juliana Rodrigues Beal

      • Abstract

      Loading...

    • +

      P82.03 - Immunotherapy in Combination with Hypofractionated Radiotherapy for Lung Cancer: A Real-World Experience

      00:00 - 00:00  |  Presenting Author(s): Naveen Mummudi

      • Abstract

      Loading...

    • +

      P82.04 - Adaptive Radiation Therapy with Consolidation Sintilimab in Stage III NSCLC: Challenges in Recruiting Patients for Adjuvant Immunotherapy

      00:00 - 00:00  |  Presenting Author(s): Yinnan Meng

      • Abstract

      Loading...

  • +

    P83 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Targeted Therapy

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P83.01 - Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC

      00:00 - 00:00  |  Presenting Author(s): Shengxiang Ren

      • Abstract

      Loading...

    • +

      P83.02 - Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

      00:00 - 00:00  |  Presenting Author(s): Suresh S. Ramalingam

      • Abstract

      Loading...

    • +

      P83.03 - Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation

      00:00 - 00:00  |  Presenting Author(s): Guanghui Gao

      • Abstract

      Loading...

    • +

      P83.04 - Efficacy and Safety of Combining Programmed Cell Death-1 Inhibitor and Anti-Angiogenic Agent as Subsequent Therapy for Advanced NSCLC

      00:00 - 00:00  |  Presenting Author(s): Ziyi Xu

      • Abstract

      Loading...

  • +

    P84 - Targeted Therapy - Clinically Focused - ALK

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P84.01 - The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients.

      00:00 - 00:00  |  Presenting Author(s): Laura Mezquita

      • Abstract

      Loading...

    • +

      P84.02 - A Phase II Trial of Alectinib-Refractory Non-Small-Cell Lung Cancer with EML4-ALK Fusion Genes; Okayama Lung Cancer Study Group 1405

      00:00 - 00:00  |  Presenting Author(s): Toshihide Yokoyama

      • Abstract

      Loading...

    • +

      P84.03 - GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

      00:00 - 00:00  |  Presenting Author(s): Nir Peled

      • Abstract

      Loading...

    • +

      P84.04 - HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis

      00:00 - 00:00  |  Presenting Author(s): Fang Wu

      • Abstract

      Loading...

    • +

      P84.05 - Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial

      00:00 - 00:00  |  Presenting Author(s): Byoung Chul Cho

      • Abstract

      Loading...

    • +

      P84.06 - Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study

      00:00 - 00:00  |  Presenting Author(s): Alexis Cortot

      • Abstract

      Loading...

    • +

      P84.07 - Distribution and Therapeutic Outcomes of Intergenic Sequence-ALK Fusion and Coexisting ALK Fusions in Lung Adenocarcinoma Patients

      00:00 - 00:00  |  Presenting Author(s): Meijuan Huang

      • Abstract

      Loading...

    • +

      P84.08 - First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer: A Network Meta-Analysis

      00:00 - 00:00  |  Presenting Author(s): Huamao M Lin

      • Abstract

      Loading...

    • +

      P84.09 - Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC

      00:00 - 00:00  |  Presenting Author(s): Ross Soo

      • Abstract

      Loading...

    • +

      P84.10 - The Impact of 3rd-Line ALK Inhibitors in ALK Positive NSCLC in Real-World Data

      00:00 - 00:00  |  Presenting Author(s): Mor Moskovitz

      • Abstract

      Loading...

    • +

      P84.11 - Real-World Brigatinib Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in the United States

      00:00 - 00:00  |  Presenting Author(s): Huamao M Lin

      • Abstract

      Loading...

    • +

      P84.12 - Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor

      00:00 - 00:00  |  Presenting Author(s): Camila Bragança Xavier

      • Abstract

      Loading...

    • +

      P84.13 - Organoid Used as Preclinical Modal in ALK Inhibitor Selection: Report of a Case Harbouring LRRTM4–ALK Fusion

      00:00 - 00:00  |  Presenting Author(s): Ziqi Jia

      • Abstract

      Loading...

    • +

      P84.14 - Identification of Mechanisms of Resistance to ALK Inhibitors. Next-Generation Sequencing-Based Liquid Biopsy Profiling.

      00:00 - 00:00  |  Presenting Author(s): Atocha Romero

      • Abstract

      Loading...

    • +

      P84.15 - Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China

      00:00 - 00:00  |  Presenting Author(s): Xue Yang

      • Abstract

      Loading...

    • +

      P84.16 - Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenting Author(s): Yago Garitaonaindía

      • Abstract

      Loading...

    • +

      P84.17 - Impacts of Different EML4-ALK Variants on the Efficacy of ALK Inhibitors in ALK Positive NSCLC——A Real-World Study in China.

      00:00 - 00:00  |  Presenting Author(s): Zihua Zou

      • Abstract

      Loading...

    • +

      P84.18 - Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement

      00:00 - 00:00  |  Presenting Author(s): Zhiwei Xiao

      • Abstract

      Loading...

    • +

      P84.19 - A Review of Clinical Outcomes of Irish Patients With ALK Rearranged NSCLC

      00:00 - 00:00  |  Presenting Author(s): Hazel O'Sullivan

      • Abstract

      Loading...

    • +

      P84.20 - VATS Right Upper Lobectomy for Advanced Non-Small Cell Lung Cancer After ALK-Tyrosine Kinase Inhibitor Administration.

      00:00 - 00:00  |  Presenting Author(s): Kozo Yamamoto

      • Abstract

      Loading...

    • +

      P84.21 - Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient

      00:00 - 00:00  |  Presenting Author(s): Flavia Amaral Duarte

      • Abstract

      Loading...

    • +

      P84.22 - Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina

      00:00 - 00:00  |  Presenting Author(s): Diego Kaen

      • Abstract

      Loading...

    • +

      P84.23 - The Safety and Toxicities of ALK -TKIs in ALK-Positive NSCLC: A Systematic Review and Pool Analysis

      00:00 - 00:00  |  Presenting Author(s): Kewei Ma

      • Abstract

      Loading...

  • +

    P85 - Targeted Therapy - Clinically Focused - MET

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P85.01 - Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC

      00:00 - 00:00  |  Presenting Author(s): Julien Mazieres

      • Abstract

      Loading...

    • +

      P85.02 - NGS could not Replace FISH Regarding to MET Amplification as an Optimal Biomarker

      00:00 - 00:00  |  Presenting Author(s): lunxi Peng

      • Abstract

      Loading...

    • +

      P85.03 - PD-L1 Expression and Efficacy of Immunotherapy in Japanese Patients with NSCLC Harboring MET Exon 14 Skipping Mutation.

      00:00 - 00:00  |  Presenting Author(s): Yasuhiro Kato

      • Abstract

      Loading...

    • +

      P85.04 - Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis 

      00:00 - 00:00  |  Presenting Author(s): Ji-Youn Han

      • Abstract

      Loading...

    • +

      P85.05 - MET Exon 14 Skipping Mutation Positive Non-Small Cell Lung Cancer: A Population-Based Cohort

      00:00 - 00:00  |  Presenting Author(s): Selina K Wong

      • Abstract

      Loading...

    • +

      P85.06 - Clinical and Genomic Features of Middle Intensity cMET Stain of Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenting Author(s): Xiaorong Dong

      • Abstract

      Loading...

    • +

      P85.07 - Neutrophils Counts Deregulated by C-met TKIs and the Variation Predicts Treatment Response in NSCLC

      00:00 - 00:00  |  Presenting Author(s): Xiao-Rong Yang

      • Abstract

      Loading...

  • +

    P86 - Targeted Therapy - Clinically Focused - New Target

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P86.01 - Phase 1 Study of the AXL Inhibitor DS-1205 in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC

      00:00 - 00:00  |  Presenting Author(s): James Chih-Hsin Yang

      • Abstract

      Loading...

    • +

      P86.02 - Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study

      00:00 - 00:00  |  Presenting Author(s): Yan Wang

      • Abstract

      Loading...

    • +

      P86.03 - A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations

      00:00 - 00:00  |  Presenting Author(s): Hussein Sweiti

      • Abstract

      Loading...

    • +

      P86.04 - The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenting Author(s): Fen Wang

      • Abstract

      Loading...

    • +

      P86.05 - In Vitro Validation Study for HER2 Mutations Identified in Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

      00:00 - 00:00  |  Presenting Author(s): Akira Hamada

      • Abstract

      Loading...

    • +

      P86.06 - A Phase I Study of Anlotinib Combined with Platinum-Pemetrexed in Untreated Non-Squamous Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenting Author(s): Meijuan Huang

      • Abstract

      Loading...

    • +

      P86.07 - CDK12 Mutated Extensive Stage Small Cell Lung Cancer Showed an Exceptional Response to Olaparib and Paclitaxel

      00:00 - 00:00  |  Presenting Author(s): Jin Young Hwang

      • Abstract

      Loading...

    • +

      P86.08 - Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors

      00:00 - 00:00  |  Presenting Author(s): Alison M Schram

      • Abstract

      Loading...

    • +

      P86.09 - A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC

      00:00 - 00:00  |  Presenting Author(s): Jianping Xiong

      • Abstract

      Loading...

    • +

      P86.10 - Real-World Efficacy and Safety of Anlotinib with and without Immunotherapy in Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenting Author(s): Qi Xiong

      • Abstract

      Loading...

    • +

      P86.11 - A Real-World Feasibility Study of Patients with Solid Tumors Harboring NRG1 Gene Fusions: NSCLC Subset Analysis

      00:00 - 00:00  |  Presenting Author(s): Ajeet Gajra

      • Abstract

      Loading...

    • +

      P86.12 - Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenting Author(s): Nahor Haddish-Berhane

      • Abstract

      Loading...

    • +

      P86.13 - Anlotinib is Active for the Patients Failed from the Prior Bevacizumab Treatment: Anti-Angiogenic Therapy might be Cross-Line Used

      00:00 - 00:00  |  Presenting Author(s): Jiang Zhu

      • Abstract

      Loading...

    • +

      P86.14 - Next-Generation Sequencing Guided the Gene Mutations Associated with mTOR-Inhibitors in Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenting Author(s): Lin Wu

      • Abstract

      Loading...

    • +

      P86.15 - Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan

      00:00 - 00:00  |  Presenting Author(s): Gee-Chen Chang

      • Abstract

      Loading...

    • +

      P86.16 - Rationale of a Phase II Trial of Nivolumab Combined with Anlotinib in Advanced NSCLC Previously Treated with Immunotherapy

      00:00 - 00:00  |  Presenting Author(s): Baohui Han

      • Abstract

      Loading...

    • +

      P86.17 - Continuous Administration of Low-Dose Apatinib Combined With WBRT for Non-Small Cell Lung Cancer With Symptomatic Brain Metastases

      00:00 - 00:00  |  Presenting Author(s): Yu-ming Jia

      • Abstract

      Loading...

    • +

      P86.18 - Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.

      00:00 - 00:00  |  Presenting Author(s): Juan Bautista Blaquier

      • Abstract

      Loading...

    • +

      P86.19 - Anlotinib in Advanced Lung Squamous Cell Carcinoma: A Real World Study

      00:00 - 00:00  |  Presenting Author(s): shujie Song

      • Abstract

      Loading...

    • +

      P86.20 - The Prevalence of NTRK1 Fusion in a Chinese Lung Cancer Cohort

      00:00 - 00:00  |  Presenting Author(s): Zhifang Liu

      • Abstract

      Loading...

    • +

      P86.21 - Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC

      00:00 - 00:00  |  Presenting Author(s): Shuchen Chen

      • Abstract

      Loading...

    • +

      P86.22 - Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

      00:00 - 00:00  |  Presenting Author(s): Yong Fang

      • Abstract

      Loading...

    • +

      P86.23 - Clinical Efficacy Analysis of Apatinib as a Second-Or Further-Line Treatment in Patients With Advanced NSCLC

      00:00 - 00:00  |  Presenting Author(s): Kewei Ma

      • Abstract

      Loading...

  • +

    P87 - Targeted Therapy - Clinically Focused - RET

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P87.01 - Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)

      00:00 - 00:00  |  Presenting Author(s): Nir Peled

      • Abstract

      Loading...

    • +

      P87.02 - AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC

      00:00 - 00:00  |  Presenting Author(s): Benjamin Besse

      • Abstract

      Loading...

    • +

      P87.03 - Characteristics and Outcomes of RET-Rearranged Non-Small Cell Lung Cancer from China: A Retrospective Study of Real-World 

      00:00 - 00:00  |  Presenting Author(s): mina Zhang

      • Abstract

      Loading...

    • +

      P87.04 - Chemotherapy and Immunotherapy Outcomes of RET-Rearranged Lung Cancers: A Case Series

      00:00 - 00:00  |  Presenting Author(s): Estelamari Rodriguez

      • Abstract

      Loading...

    • +

      P87.05 - RET-Rearranged Squamous Cell Carcinoma of the Lung Responding to First-Line Immunotherapy plus Chemotherapy

      00:00 - 00:00  |  Presenting Author(s): qing-yun Gao

      • Abstract

      Loading...

  • +

    P88 - Targeted Therapy - Clinically Focused - ROS1

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P88.01 - Comprehensive Profiling of ROS1 Fusions in Chinese Non-Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenting Author(s): Hanlin Xu

      • Abstract

      Loading...

    • +

      P88.02 - SDC4-ROS1 Fusion as a Mechanism of Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma

      00:00 - 00:00  |  Presenting Author(s): Chun-wei Xu

      • Abstract

      Loading...

    • +

      P88.03 - Asymptomatic COVID-19 in a ROS1 positive Non Small Cell Lung Cancer.

      00:00 - 00:00  |  Presenting Author(s): Ananda Datta

      • Abstract

      Loading...

    • +

      P88.04 - Successful Low-Dose Treatment for Patients with ROS1-Rearranged NSCLC who Developed Crizotinib-Related Heart Failure.

      00:00 - 00:00  |  Presenting Author(s): Takahiko Hashimoto

      • Abstract

      Loading...

    • +

      P88.05 - A Recommended one-step Targeted Sequencing Technology for Identification of a Dual CD74-ROS1 in NSCLC

      00:00 - 00:00  |  Presenting Author(s): Quan Lin

      • Abstract

      Loading...